2021
DOI: 10.26442/00403660.2021.01.200593
|View full text |Cite
|
Sign up to set email alerts
|

Refractory and resistant hypertension in patients with type 2 diabetes mellitus: differences in metabolic profile and endothelial function

Abstract: Aim. To determine the prevalence of refractory hypertension (RfH) in patients with and without type 2 diabetes mellitus (DM), as well as to evaluate whether diabetic patients with RfH significant differ from those with uncontrolled resistant hypertension (RH) in clinical phenotype, metabolic profile and endothelial function. Materials and methods. The study included 193 patients with RH: RH 74 patients with diabetes and 119 patients without DM. Uncontrolled RH and RfH were defined by the presence of unco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
1
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 38 publications
0
1
0
1
Order By: Relevance
“…The mean ± standard deviation (X ± S) was used to express the results using independent sample t-test. Computational and Mathematical Methods in Medicine blocker, which can fully block β receptors and also selectively block α1 receptors without endogenous sympathomimetic activity and peripheral β agonism [10]. Carvedilol, as a third-generation β-blocker, has characteristics unmatched by other β2-blockers and is widely used in the treatment of hypertension, congestive heart failure, and coronary artery disease with proven efficacy [11].…”
Section: Discussionmentioning
confidence: 99%
“…The mean ± standard deviation (X ± S) was used to express the results using independent sample t-test. Computational and Mathematical Methods in Medicine blocker, which can fully block β receptors and also selectively block α1 receptors without endogenous sympathomimetic activity and peripheral β agonism [10]. Carvedilol, as a third-generation β-blocker, has characteristics unmatched by other β2-blockers and is widely used in the treatment of hypertension, congestive heart failure, and coronary artery disease with proven efficacy [11].…”
Section: Discussionmentioning
confidence: 99%
“…Суточная экскреция катехоламинов в моче, в отличие от уровня β-АРМэ, в сравниваемых группах была сопоставимой. При этом следует отметить, что сведения о различиях уровня катехоламинов у больных рфАГ и РАГ весьма противоречивы [5,13], что может быть обусловлено ограничениями данного метода в оценке симпатической активности, а также особенностями выборок пациентов. Прямых корреляционных связей β-АРМэ с уровнем суточной экскреции катехоламинов мы также не обнаружили.…”
Section: Discussionunclassified